- Home
- ATHA vs BRLT Comparison
ATHA vs BRLT Comparison
Compare ATHA & BRLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATHA
- BRLT
- Stock Information
- Founded
- ATHA 2011
- BRLT 2005
- Country
- ATHA United States
- BRLT United States
- Employees
- ATHA N/A
- BRLT N/A
- Industry
- ATHA Medicinal Chemicals and Botanical Products
- BRLT Consumer Specialties
- Sector
- ATHA Health Care
- BRLT Consumer Discretionary
- Exchange
- ATHA Nasdaq
- BRLT Nasdaq
- Market Cap
- ATHA 21.0M
- BRLT 22.6M
- IPO Year
- ATHA 2020
- BRLT 2021
- Fundamental
- Price
- ATHA $0.43
- BRLT $1.37
- Analyst Decision
- ATHA Buy
- BRLT Hold
- Analyst Count
- ATHA 4
- BRLT 5
- Target Price
- ATHA $11.25
- BRLT $2.40
- AVG Volume (30 Days)
- ATHA 210.5K
- BRLT 95.6K
- Earning Date
- ATHA 03-04-2025
- BRLT 03-12-2025
- Dividend Yield
- ATHA N/A
- BRLT N/A
- EPS Growth
- ATHA N/A
- BRLT N/A
- EPS
- ATHA N/A
- BRLT 0.03
- Revenue
- ATHA N/A
- BRLT $426,982,000.00
- Revenue This Year
- ATHA N/A
- BRLT N/A
- Revenue Next Year
- ATHA N/A
- BRLT $1.04
- P/E Ratio
- ATHA N/A
- BRLT $49.86
- Revenue Growth
- ATHA N/A
- BRLT N/A
- 52 Week Low
- ATHA $0.41
- BRLT $1.25
- 52 Week High
- ATHA $4.21
- BRLT $3.21
- Technical
- Relative Strength Index (RSI)
- ATHA 34.62
- BRLT 31.80
- Support Level
- ATHA $0.42
- BRLT $1.25
- Resistance Level
- ATHA $0.46
- BRLT $1.75
- Average True Range (ATR)
- ATHA 0.04
- BRLT 0.12
- MACD
- ATHA -0.00
- BRLT -0.03
- Stochastic Oscillator
- ATHA 10.85
- BRLT 21.82
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.
About BRLT Brilliant Earth Group Inc.
Brilliant Earth Group Inc designs, procures and sells ethically-sourced diamonds, gemstones and jewelry online and through showrooms. Its sales consist of revenue from diamond, gemstone, and jewelry retail sales. The company sells its products in the U.S. and other international countries, of which a majority of revenue is derived from the U.S.